SWTX SpringWorks Therapeutics
- 45.530
- +1.330+3.01%
- 45.530
- 0.0000.00%
SpringWorks Therapeutics News
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
SpringWorks Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $74
Barclays Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $63
Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Springworks Therapeutics (SWTX)
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)
Springworks Therapeutics: A Buy Rating on Ogsiveo's Success and Promising Pipeline
SpringWorks Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Goldman Sachs Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Analyst Ratings
Analyst Ratings for SpringWorks Therapeutics
Buy Rating on Springworks Therapeutics With Increased Price Target Following FDA Approval of Ogsiveo
Analysts' Top Healthcare Picks: Avidity Biosciences (RNA), Springworks Therapeutics (SWTX)
Buy Rating Affirmed for Springworks Therapeutics on OGSIVEO's Superior Efficacy and FDA Approval
SpringWorks Therapeutics Analyst Ratings
Buy Rating for Springworks Therapeutics on Strong FDA Approval and Market Potential
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $52
SpringWorks Therapeutics Analyst Ratings
Springworks Therapeutics Receives Buy Rating Based on Promising Mirdametinib Drug Efficacy and Potential Market Dominance
Analysis
Price Target
No Data
